News from index pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 15, 2023, 05:18 ET InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced positive results from a pharmacokinetic (PK) study with cobitolimod in patients with moderate ...

Mar 15, 2023, 05:14 ET InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced positive results from a pharmacokinetic (PK) study with cobitolimod in patients with moderate ...

Feb 27, 2023, 06:28 ET InDex Pharmaceuticals to attend the ECCO 2023 congress

InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis...

Feb 27, 2023, 06:26 ET InDex Pharmaceuticals to attend the ECCO 2023 congress

InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis...

Feb 14, 2023, 06:55 ET InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod

InDex Pharmaceuticals Holding AB (publ) is today making a presentation with CEO Jenny Sundqvist available in light of the press release issued...

Feb 14, 2023, 06:52 ET InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod

InDex Pharmaceuticals Holding AB (publ) is today making a presentation with CEO Jenny Sundqvist available in light of the press release issued...

Jan 27, 2023, 08:25 ET InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with...

Jan 27, 2023, 08:24 ET InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with...

Oct 10, 2022, 07:54 ET Jenny Sundqvist new CEO of InDex Pharmaceuticals

InDex Pharmaceuticals Holding AB (publ) today announced that the Board of Directors has named Jenny Sundqvist as new CEO. Jenny comes from a position ...

Oct 10, 2022, 07:51 ET Jenny Sundqvist new CEO of InDex Pharmaceuticals

InDex Pharmaceuticals Holding AB (publ) today announced that the Board of Directors has named Jenny Sundqvist as new CEO. Jenny comes from a position ...

Oct 05, 2022, 06:35 ET InDex Pharmaceuticals to exhibit at United European Gastroenterology Week

InDex Pharmaceuticals Holding AB (publ) today announced that the company will be exhibiting at the United European Gastroenterology Week (UEGW)...

Oct 05, 2022, 06:30 ET InDex Pharmaceuticals to exhibit at United European Gastroenterology Week

InDex Pharmaceuticals Holding AB (publ) today announced that the company will be exhibiting at the United European Gastroenterology Week (UEGW)...

Aug 16, 2022, 05:04 ET InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan

InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive feedback from the Japanese regulatory authority, the...

Jul 13, 2022, 04:49 ET InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...

May 12, 2022, 05:18 ET InDex Pharmaceuticals to exhibit at Digestive Disease Week

InDex Pharmaceuticals Holding AB (publ) today announced that the company will be exhibiting at the Digestive Disease Week (DDW) May 21-24, 2022 in...

Apr 28, 2022, 08:23 ET Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the "Company"), are hereby summoned to the Annual General Meeting on Wednesday ...

Mar 14, 2022, 03:24 ET InDex Pharmaceuticals prepares for commercialisation of cobitolimod

InDex Pharmaceuticals Holding AB (publ) is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic...

Feb 15, 2022, 07:49 ET Invitation to InDex Pharmaceuticals' Capital Markets Day on March 14, 2022

InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to a Capital Markets Day on March 14, 2022. The Capital Markets Day...

Dec 08, 2021, 03:58 ET InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical pharmacokinetic study (PK study)...

Nov 24, 2021, 06:50 ET InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis

InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the pivotal phase III study CONCLUDE. The study...

Nov 24, 2021, 02:20 ET InDex Pharmaceuticals Holding AB (publ) interim report January - September 2021

"We have now several clinics activated in the phase III study CONCLUDE and look forward to enrol the first patient in the near term", says Peter...

Nov 16, 2021, 04:26 ET InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...

Nov 10, 2021, 02:23 ET InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting

InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2022 Annual General Meeting. The...

Nov 09, 2021, 07:47 ET InDex Pharmaceuticals gets new patent for cobitolimod granted in the US

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...

Aug 24, 2021, 03:58 ET InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to start the phase III...